Literature DB >> 2854255

Structure-activity relationship studies of hemicholinium (HC-3) congeners.

J G Cannon1, T M Lee, Y Chang, A M Nyanda, B Bhattacharyya, J R Flynn, T Chatterjee, R K Bhatnagar, J P Long.   

Abstract

In a continuing investigation of structural requirements for hemicholinium-like activity (inhibition of neuromuscular transmission due to inhibition of uptake of choline into nerve terminals), some additional molecular modifications of hemicholinium ("HC-3"; structure 1) were made. The target compounds were prepared by standard one- or two-step sequences. Noncyclic acetal moieties in general permitted retention of pharmacological activity, as did concomitant replacement of the central biphenyl "spacer" by other bulky cyclic groupings and replacement of the oxazinium rings by piperidine or 4-methylpiperidine. However, these modifications generally produced compounds of a lower potency. Replacement of the biphenyl moiety of HC-3 with polyakylene chains permitted retention of a considerable degree of activity. In these target compounds, the two quaternary nitrogens can exist the same distance apart (approximately 14 A) as in the hemicholinium molecule. The ditertiary amino congener of a pharmacologically active bis-quaternary oxazinium compound was almost completely inactive. To date, only one tertiary amine has been found which displays a significant degree of hemicholinium-like activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854255     DOI: 10.1023/a:1015955527100

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Pharmacologic evaluation and structure activity relationships of a series of hemicholinium-3 (HC-3) analogs.

Authors:  B Bhattacharyya; M D Sokoll; J G Cannon; J P Long
Journal:  Arch Int Pharmacodyn Ther       Date:  1987-07

2.  Sodium-dependent high affinity choline uptake: a regulatory step in the synthesis of acetylcholine.

Authors:  J R Simon; S Atweh; M J Kuhar
Journal:  J Neurochem       Date:  1976-05       Impact factor: 5.372

3.  A new series of cholinesterase inhibitors.

Authors:  J P LONG; F W SCHUELER
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1954-02

4.  High affinity transport of choline into synaptosomes of rat brain.

Authors:  H I Yamamura; S H Snyder
Journal:  J Neurochem       Date:  1973-12       Impact factor: 5.372

5.  Studies of DMAE-induced potentiation of the pressor and contractile responses to exogenous norepinephrine in normal and reserpine treated animals.

Authors:  S Greenberg; J P Long
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-06

6.  Evaluation of 4-methylpiperidine analogs of hemicholinium-3.

Authors:  C E Tedford; D Reed; B Bhattacharyya; P Bhalla; J G Cannon; J P Long
Journal:  Eur J Pharmacol       Date:  1986-09-09       Impact factor: 4.432

7.  Enhanced responses to tyramine and angiotensin produced by 4,4'-biphenylene bis-((2-oxoethylene)-bis-(2,2-diethoxylethyl)dimethylammonium bromide) (DMAE).

Authors:  S Greenberg; J P Long
Journal:  Eur J Pharmacol       Date:  1971-06       Impact factor: 4.432

8.  Antagonism of ganglionic stimulants by alpha, alpha'-bis-(dimethylammoniumacetaldehyde diethylacetal)-p,p'-diacetylbiphenyl bromide (DMAE).

Authors:  S Wong; J P Long
Journal:  J Pharmacol Exp Ther       Date:  1968-11       Impact factor: 4.030

9.  Structure-activity relationship studies in the hemicholinium ('HC-3') series.

Authors:  J G Cannon; T M Lee; A M Nyanda; B Bhattacharyya; J P Long
Journal:  Drug Des Deliv       Date:  1987-02

10.  A-4, a bis tertiary amine derivative of hemicholinium-3 produces in vivo reduction of acetylcholine in rat brain regions.

Authors:  C E Tedford; M J Schott; J R Flynn; J G Cannon; J P Long
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

View more
  1 in total

Review 1.  Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.

Authors:  Sean P Arlauckas; Anatoliy V Popov; E James Delikatny
Journal:  Prog Lipid Res       Date:  2016-04-09       Impact factor: 16.195

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.